Genomtec SaGPW: GMT

GMT: Patent expansion, cost cuts, and narrowed loss set the stage for commercialization in 2026

· Issued by Genomtec SA

2025 saw major organizational changes, patent expansion, and cost reductions, with a narrowed net loss and increased equity. Commercialization of key projects is the main focus, supported by grants and new share issues, while risks remain tied to early-stage development and funding needs.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Earlier from Genomtec Sa

All Genomtec Sa news releases